Janssen, Julie M.
Van Calsteren, Kristel
Dorlo, Thomas P. C.
Halaska, Michael J.
Fruscio, Robert
Ottevanger, Petronella
Schröder, Carolien P.
Boere, Ingrid
Witteveen, Petronella O.
Painter, Rebecca C.
Bekkers, Ruud
Drochytek, Vit
Beijnen, Jos H.
Huitema, Alwin D. R.
Amant, Frederic C. H.
Funding for this research was provided by:
European Research Council (647047)
Article History
Accepted: 30 October 2020
First Online: 28 January 2021
Declarations
:
: Funding for the INCIP registry, sample bioanalysis and sample logistics was provided by the European Research Council under the European Union’s Horizon 2020 research and innovation programme (grant agreement number 647047), the Research Foundation-Flanders and the Belgian Cancer Plan, Ministry of Health, Belgium.
: Frédéric Amant is a senior clinical investigator for the Research Fund-Flanders; Kristel Van Calsteren received a clinical research fund from the University Hospitals Leuven; Thomas Dorlo was personally supported by a Dutch Research Council (NWO)/ZonMw Veni grant; Michael J. Halaska was supported by the Charles University research project Progres Q28 and Q34; and Jos Beijnen is a part-time employee, patent holder (partly) and stock holder (indirectly) of Modra Pharmaceuticals BV, a spin-out company developing oral taxane formulations and therapies, which is not related to the submitted work. Julie M. Janssen, Robert Fruscio, Petronella Ottevanger, Carolien P. Schröder, Ingrid Boere, Petronella O. Witteveen, Rebecca C. Painter, Ruud Bekkers, Vit Drochytek and Alwin D.R. Huitema have no conflicts of interest to declare.
: The data used in this study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by institutional review boards and independent ethics committees at participating 137 institutions.
: Informed consent was obtained from all individual participants included in the study.
: All individual participants signed informed consent regarding publishing their data.
: Not applicable.
: Not applicable.
: JJ, TD and AH performed the analysis, data interpretation and writing of the manuscript. KVC and FA designed the study, included patients, contributed to the writing of the manuscript, and provided financial support. MH, RF, PO, CS, IB, PW, RP, RB and VD included patients and contributed to the writing of the manuscript. JB contributed to drug analysis and writing of the manuscript.